secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0000078003-24-000195
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00
------------------------------------------------------------------

- Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.
- Full-year 2025 adjusted diluted EPS guidance range of $2.80 to $3.00, reflecting operational growth of 10% to 18%.
- Achieved goal of $4.0 billion in net cost savings through 2024; expects an additional $500 million in savings in 2025.
- First phase of manufacturing optimization program on track to deliver initial net cost savings in latter part of 2025.
- Reaffirmed full-year 2024 guidance: revenue $61-64B, adjusted EPS $2.75-2.95.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000195/0000078003-24-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000195/pfe-20241217.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer